Access
To read this story in full you will need to login or make a payment (see right).
Letter
Nature 453, 1258-1261 (26 June 2008) | doi:10.1038/nature06956; Received 14 February 2008; Accepted 1 April 2008; Published online 14 May 2008
Open Innovation Challenges
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
nature jobs
Multiple Postdoctoral Positions
- University of Iowa
- Coralville, Iowa, USA
Associate Scientific Manager / Scientific Manager-Organic / Medicinal Chemistry
- Syngene International
- Bangalore, Karnataka 560099 India
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants
Patrick J. Collins1, Lesley F. Haire1, Yi Pu Lin1, Junfeng Liu1, Rupert J. Russell2, Philip A. Walker1, John J. Skehel1, Stephen R. Martin1, Alan J. Hay1 & Steven J. Gamblin1
- MRC-National Institute for Medical Research, Mill Hill, London NW7 1AA, UK
- Interdisciplinary Centre for Human and Avian Influenza Research, School of Biology, University of St Andrews, Fife KY16 9ST, UK
Correspondence to: Steven J. Gamblin1 Correspondence and requests for materials should be addressed to S.J.G. (Email: sgambli@nimr.mrc.ac.uk).
Abstract
The potential impact of pandemic influenza makes effective measures to limit the spread and morbidity of virus infection a public health priority. Antiviral drugs are seen as essential requirements for control of initial influenza outbreaks caused by a new virus, and in pre-pandemic plans there is a heavy reliance on drug stockpiles. The principal target for these drugs is a virus surface glycoprotein, neuraminidase, which facilitates the release of nascent virus and thus the spread of infection. Oseltamivir (Tamiflu) and zanamivir (Relenza) are two currently used neuraminidase inhibitors that were developed using knowledge of the enzyme structure1, 2. It has been proposed that the closer such inhibitors resemble the natural substrate, the less likely they are to select drug-resistant mutant viruses that retain viability3. However, there have been reports of drug-resistant mutant selection in vitro4 and from infected humans5, 6. We report here the enzymatic properties and crystal structures of neuraminidase mutants from H5N1-infected patients that explain the molecular basis of resistance. Our results show that these mutants are resistant to oseltamivir but still strongly inhibited by zanamivir owing to an altered hydrophobic pocket in the active site of the enzyme required for oseltamivir binding. Together with recent reports of the viability and pathogenesis of H5N1 (ref. 7) and H1N1 (ref. 8) viruses with neuraminidases carrying these mutations, our results indicate that it would be prudent for pandemic stockpiles of oseltamivir to be augmented by additional antiviral drugs, including zanamivir.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Structural biology Antiviral drugs fit for a purposeNature News and Views (07 Sep 2006)
A rational attack on influenzaNature News and Views (03 Jun 1993)
See all 4 matches for News And ViewsRESEARCH
Avian flu Isolation of drug-resistant H5N1 virusNature Brief Communication (20 Oct 2005)
See all 24 matches for Research
